Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
Ajore R, Niroula A, Pertesi M, Cafaro C, Thodberg M, Went M, Bao EL, Duran-Lozano L, Lopez de Lapuente Portilla A, Olafsdottir T, Ugidos-Damboriena N, Magnusson O, Samur M, Lareau CA, Halldorsson GH, Thorleifsson G, Norddahl GL, Gunnarsdottir K, Försti A, Goldschmidt H, Hemminki K, van Rhee F, Kimber S, Sperling AS, Kaiser M, Anderson K, Jonsdottir I, Munshi N, Rafnar T, Waage A, Weinhold N, Thorsteinsdottir U, Sankaran VG, Stefansson K, Houlston R, Nilsson B. Ajore R, et al. Among authors: van rhee f. Nat Commun. 2022 Dec 13;13(1):7725. doi: 10.1038/s41467-022-35411-1. Nat Commun. 2022. PMID: 36513657 Free PMC article. No abstract available.
Insights into the etiology of Castleman disease.
van Rhee F, Fajgenbaum D. van Rhee F, et al. Blood. 2024 May 2;143(18):1789-1790. doi: 10.1182/blood.2023023716. Blood. 2024. PMID: 38696194 No abstract available.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Lee HC, et al. Among authors: van rhee f. Eur J Haematol. 2024 Apr 23. doi: 10.1111/ejh.14214. Online ahead of print. Eur J Haematol. 2024. PMID: 38654611
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Guo W, Strouse C, Mery D, Siegel ER, Munshi MN, Ashby TC, Cheng Y, Sun F, Wanchai V, Zhang Z, Bailey C, Alapat DV, Peng H, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Guo W, et al. Among authors: van rhee f. Cancers (Basel). 2024 Mar 11;16(6):1116. doi: 10.3390/cancers16061116. Cancers (Basel). 2024. PMID: 38539451 Free PMC article.
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R. Mohan M, et al. Among authors: van rhee f. Blood Cancer J. 2024 Mar 5;14(1):35. doi: 10.1038/s41408-024-01003-z. Blood Cancer J. 2024. PMID: 38443345 Free PMC article.
Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease.
Nishikori A, Nishimura MF, Fajgenbaum DC, Nishimura Y, Maehama K, Haratake T, Tabata T, Kawano M, Nakamura N, Momose S, Sumiyoshi R, Koga T, Yamamoto H, van Rhee F, Kawakami A, Sato Y. Nishikori A, et al. Among authors: van rhee f. J Clin Pathol. 2024 Feb 20:jcp-2023-209280. doi: 10.1136/jcp-2023-209280. Online ahead of print. J Clin Pathol. 2024. PMID: 38378248
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Mohan M, et al. Among authors: van rhee f. Bone Marrow Transplant. 2024 May;59(5):647-652. doi: 10.1038/s41409-024-02233-2. Epub 2024 Feb 15. Bone Marrow Transplant. 2024. PMID: 38361116
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Guo W, et al. Among authors: van rhee f. Blood Cancer J. 2024 Feb 14;14(1):30. doi: 10.1038/s41408-024-00998-9. Blood Cancer J. 2024. PMID: 38355688 Free PMC article. No abstract available.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD Jr, Anderson KC, Zhan F, Qiu L, An G. Mao X, et al. Among authors: van rhee f. Am J Hematol. 2024 Apr;99(4):523-533. doi: 10.1002/ajh.27207. Epub 2024 Jan 21. Am J Hematol. 2024. PMID: 38247315
318 results